Navigation Links
BioMarin to Present at the Baird Health Care Conference
Date:8/30/2011

NOVATO, Calif., Aug. 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Baird Health Care Conference in New York on Wednesday, September 7, 2011 at 9:30 a.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease; and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017 The Senior Care Pharmacy ... Senate and House of Representatives that will curtail the ... (PBMs) -- from extracting retroactive direct and indirect remuneration ... (LTC) pharmacies and the Medicare program. S. ... (R-WV) and Jon Tester (D-MT), and House ...
(Date:2/22/2017)... DUBLIN , Feb 22, 2017 Research ... Devices Market Analysis & Trends - Industry Forecast to 2025" report ... The ... of around 5.2% over the next decade to reach approximately $2.1 billion ... estimates and forecasts for all the given segments on global as well ...
(Date:2/22/2017)... 2017 Henry Schein Medical today announced ... with Rijuven, which develops innovative digital medical devices, ... practitioners. CardioSleeve is a stethoscope ... sound signals, transmits real-time data to any smartphone ... to help physicians provide diagnostic interpretation of a ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... A cylindrical “pipeline” used for treating ... reach ones, according to the results of a clinical trial announced Wednesday. , ... Ricardo A. Hanel, MD, PhD, neurovascular surgeon with Baptist Health and Lyerly Neurosurgery ...
(Date:2/22/2017)... ... 22, 2017 , ... Using the power of the internet, IdrisArkette.com has managed ... a period of just 24 months, thousands of individuals interested in a medical procedure ... , “The internet is not getting quieter. In fact it’s becoming noisier by the ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... of issues related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., ... as one of a small number of neurosurgeons in Michigan performing minimally invasive ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five ... of those report that family members or friends have also commented about their ... hearing loss wear hearing aids. One reason, suggested by 89 percent of American ...
(Date:2/22/2017)... ... ... Social media marketing is transitioning from a singular person activity to a ... into this insight and more in its latest episode of its Brains Over Brawn ... with social media strategist and partner of the digital firm Med|Ed Digital Jessica Columbo. ...
Breaking Medicine News(10 mins):